

# Sebastiaan Engelborghs

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/7326532/sebastiaan-engelborghs-publications-by-year.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

301  
papers

20,697  
citations

60  
h-index

141  
g-index

356  
ext. papers

24,885  
ext. citations

6.3  
avg, IF

5.89  
L-index

#	Paper	IF	Citations
301	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum.. <i>JAMA Neurology</i> , <b>2022</b> ,	17.2	9
300	Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's disease.. <i>Molecular Neurodegeneration</i> , <b>2022</b> , 17, 27	19	1
299	Genome-Wide Association Study of Alzheimer's Disease Brain Imaging Biomarkers and Neuropsychological Phenotypes in the European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery Dataset.. <i>Frontiers in Aging Neuroscience</i> , <b>2022</b> , 14, 840651	5.3	0
298	A qualitative study with people with young-onset dementia and their family caregivers on advance care planning: A holistic, flexible, and relational approach is recommended.. <i>Palliative Medicine</i> , <b>2022</b> , 2692163221090385	5.5	1
297	Clinical application of CSF biomarkers for Alzheimer's disease: From rationale to ratios.. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2022</b> , 14, e12314	5.2	0
296	iPSC-derived cortical neurons to study sporadic Alzheimer disease: a transcriptome comparison with post-mortem brain samples.. <i>Toxicology Letters</i> , <b>2021</b> , 356, 89-89	4.4	0
295	European Academy of Neurology/European Alzheimer's Disease Consortium position statement on diagnostic disclosure, biomarker counseling, and management of patients with mild cognitive impairment. <i>European Journal of Neurology</i> , <b>2021</b> , 28, 2147-2155	6	7
294	Cortical Auditory Evoked Potentials in Cognitive Impairment and Their Relevance to Hearing Loss: A Systematic Review Highlighting the Evidence Gap. <i>Frontiers in Neuroscience</i> , <b>2021</b> , 15, 781322	5.1	
293	Inter- and Intra-Scanner Variability of Automated Brain Volumetry on Three Magnetic Resonance Imaging Systems in Alzheimer's Disease and Controls. <i>Frontiers in Aging Neuroscience</i> , <b>2021</b> , 13, 746982	5.3	1
292	Replication study of plasma proteins relating to Alzheimer's pathology. <i>Alzheimer's and Dementia</i> , <b>2021</b> , 17, 1452-1464	1.2	4
291	Time Trends of Cerebrospinal Fluid Biomarkers of Neurodegeneration in Idiopathic Normal Pressure Hydrocephalus. <i>Journal of Alzheimer's Disease</i> , <b>2021</b> , 80, 1629-1642	4.3	3
290	Vestibular Function in Older Adults With Cognitive Impairment: A Systematic Review. <i>Ear and Hearing</i> , <b>2021</b> , 42, 1119-1126	3.4	1
289	TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels. <i>Alzheimer's and Dementia</i> , <b>2021</b> , 17, 1628-1640	1.2	4
288	Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. <i>Nature Communications</i> , <b>2021</b> , 12, 3417	17.4	23
287	Plasma Proteomic Biomarkers Relating to Alzheimer's Disease: A Meta-Analysis Based on Our Own Studies. <i>Frontiers in Aging Neuroscience</i> , <b>2021</b> , 13, 712545	5.3	3
286	No association of CpG SNP rs9357140 with onset age in Belgian C9orf72 repeat expansion carriers. <i>Neurobiology of Aging</i> , <b>2021</b> , 97, 145.e1-145.e4	5.6	2
285	Contribution of homozygous and compound heterozygous missense mutations in VWA2 to Alzheimer's disease. <i>Neurobiology of Aging</i> , <b>2021</b> , 99, 100.e17-100.e23	5.6	1

284	Biomarker counseling, disclosure of diagnosis and follow-up in patients with mild cognitive impairment: A European Alzheimer's disease consortium survey. <i>International Journal of Geriatric Psychiatry</i> , <b>2021</b> , 36, 324-333	3.9	9
283	Diagnostic Evaluation of Dementia <b>2021</b> , 31-55		
282	Lumbar Puncture: Consensus Guidelines. <i>Neuromethods</i> , <b>2021</b> , 129-135	0.4	
281	Melatonin levels in the Alzheimer's disease continuum: a systematic review. <i>Alzheimer's Research and Therapy</i> , <b>2021</b> , 13, 52	9	14
280	Contribution of rare homozygous and compound heterozygous VPS13C missense mutations to dementia with Lewy bodies and Parkinson's disease. <i>Acta Neuropathologica Communications</i> , <b>2021</b> , 9, 25	7.3	7
279	CSF and Blood Neurofilament Levels in Athletes Participating in Physical Contact Sports: A Systematic Review. <i>Neurology</i> , <b>2021</b> , 96, 705-715	6.5	3
278	Hippocampal Sclerosis in Frontotemporal Dementia: When Vascular Pathology Meets Neurodegeneration. <i>Journal of Neuropathology and Experimental Neurology</i> , <b>2021</b> , 80, 313-324	3.1	1
277	CSF Proteomic Alzheimer's Disease-Predictive Subtypes in Cognitively Intact Amyloid Negative Individuals. <i>Proteomes</i> , <b>2021</b> , 9,	4.6	2
276	Family-based exome sequencing identifies RBM45 as a possible candidate gene for frontotemporal dementia and amyotrophic lateral sclerosis. <i>Neurobiology of Disease</i> , <b>2021</b> , 156, 105421	7.5	0
275	Neuropsychiatric Symptoms in Mild Cognitive Impairment and Dementia Due to AD: Relation With Disease Stage and Cognitive Deficits. <i>Frontiers in Psychiatry</i> , <b>2021</b> , 12, 707580	5	4
274	Investigation of the role of matrix metalloproteinases in the genetic etiology of Alzheimer's disease. <i>Neurobiology of Aging</i> , <b>2021</b> , 104, 105.e1-105.e6	5.6	3
273	Diagnostic Performance of Automated MRI Volumetry by icobrain dm for Alzheimer's Disease in a Clinical Setting: A REMEMBER Study. <i>Journal of Alzheimer's Disease</i> , <b>2021</b> , 83, 623-639	4.3	3
272	Serum Daytime Melatonin Levels Reflect Cerebrospinal Fluid Melatonin Levels in Alzheimer's Disease but Are Not Correlated with Cognitive Decline. <i>Journal of Alzheimer's Disease</i> , <b>2021</b> , 83, 693-704	4.3	1
271	Premature termination codon mutations in ABCA7 contribute to Alzheimer's disease risk in Belgian patients. <i>Neurobiology of Aging</i> , <b>2021</b> , 106, 307.e1-307.e7	5.6	3
270	Neurogranin as biomarker in CSF is non-specific to Alzheimer's disease dementia. <i>Neurobiology of Aging</i> , <b>2021</b> , 108, 99-109	5.6	3
269	Identification of plasma proteome signatures associated with ATN framework using SOMAscan. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, e036954	1.2	1
268	Biomarker counseling, disclosure of diagnosis, and follow-up in patients with mild cognitive impairment: A European survey of EADC centers. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, e039026	1.2	
267	Recessive missense variants in VWA2 increase risk of developing Alzheimer's disease. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, e039791	1.2	

266	ABCA7 mutations are major contributors to Alzheimer's disease in Belgian patients. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, e040227	1.2	
265	ABCA7 PTC mutation carriers present with Alzheimer's disease pathology and cerebral amyloid angiopathy. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, e041513	1.2	
264	Cerebrospinal fluid amyloid status and affective symptoms in mild cognitive impairment. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, e041961	1.2	
263	Neurofilament light and cognitive performance: Associations with amyloid and vascular pathologies in individuals with mild cognitive impairment. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, e042739	1.2	
262	3xTg Alzheimer's disease mice are more susceptible to induced seizures. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, e044096	1.2	1
261	DNA methylation differences associated with peripheral biomarkers in the EMIF-AD cohort. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, e045853	1.2	
260	International initiative for harmonization of cerebrospinal fluid diagnostic comments in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, e047209	1.2	1
259	A family-based genetic study identifies mutations in TLR9 impairing receptor activation: A role for innate immunity in AD pathogenesis. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, e047212	1.2	1
258	Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer's Disease Multimodal Biomarker Discovery Cohort. <i>Journal of Alzheimer's Disease</i> , <b>2020</b> , 74, 213-225	4.3	10
257	Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer's disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study. <i>Alzheimer's Research and Therapy</i> , <b>2020</b> , 12, 58	9	27
256	Mutated ATP10B increases Parkinson's disease risk by compromising lysosomal glucosylceramide export. <i>Acta Neuropathologica</i> , <b>2020</b> , 139, 1001-1024	14.3	27
255	Automated MRI volumetry as a diagnostic tool for Alzheimer's disease: Validation of icobrain dm. <i>NeuroImage: Clinical</i> , <b>2020</b> , 26, 102243	5.3	14
254	Depressive Symptoms in the Elderly-An Early Symptom of Dementia? A Systematic Review. <i>Frontiers in Pharmacology</i> , <b>2020</b> , 11, 34	5.6	22
253	A Novel Tau Antibody Detecting the First Amino-Terminal Insert Reveals Conformational Differences Among Tau Isoforms. <i>Frontiers in Molecular Biosciences</i> , <b>2020</b> , 7, 48	5.6	0
252	Cerebrospinal fluid total tau levels indicate aberrant neuronal plasticity in Alzheimer's disease <b>2020</b>		1
251	Comparing Advance Care Planning in Young-Onset Dementia in the USA vs Belgium: Challenges Partly Related to Societal Context. <i>Journal of the American Medical Directors Association</i> , <b>2020</b> , 21, 851-857	5.9	3
250	Pathophysiological subtypes of Alzheimer's disease based on cerebrospinal fluid proteomics. <i>Brain</i> , <b>2020</b> , 143, 3776-3792	11.2	16
249	Encephalitis associated with the SARS-CoV-2 virus: A case report. <i>Interdisciplinary Neurosurgery: Advanced Techniques and Case Management</i> , <b>2020</b> , 22, 100821	0.5	15

248	Genome-wide association study of Alzheimer's disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset. <i>Translational Psychiatry</i> , <b>2020</b> , 10, 403	8.6	10
247	Impact of hearing loss and vestibular decline on cognition in Alzheimer's disease: a prospective longitudinal study protocol (Gehoor, Evenwicht en Cognitie, GECKO). <i>BMJ Open</i> , <b>2020</b> , 10, e039601	3	4
246	Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology. <i>Journal of Alzheimer's Disease</i> , <b>2020</b> , 77, 1353-1368	4.3	4
245	Amyloid- $\beta$ Cerebrospinal fluid levels and the interpretation of APP, PSEN1 and PSEN2 mutations. <i>Alzheimer's Research and Therapy</i> , <b>2020</b> , 12, 108	9	9
244	Practices and opinions about disclosure of the diagnosis of Alzheimer's disease to patients with MCI or dementia: a survey among Belgian medical experts in the field of dementia. <i>Acta Neurologica Belgica</i> , <b>2020</b> , 120, 1157-1163	1.5	1
243	Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker-based case-control study. <i>PLoS Medicine</i> , <b>2020</b> , 17, e1003289	11.6	15
242	Exploring Cognitive Frailty: Prevalence and Associations with Other Frailty Domains in Older People with Different Degrees of Cognitive Impairment. <i>Gerontology</i> , <b>2020</b> , 66, 55-64	5.5	13
241	Meanings of Care Convoys: The Structure, Function, and Adequacy of Care Networks Among Frail, Community-Dwelling Older Adults. <i>Qualitative Health Research</i> , <b>2020</b> , 30, 583-597	3.9	3
240	Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker-based case-control study <b>2020</b> , 17, e1003289		
239	Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker-based case-control study <b>2020</b> , 17, e1003289		
238	Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker-based case-control study <b>2020</b> , 17, e1003289		
237	Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker-based case-control study <b>2020</b> , 17, e1003289		
236	Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker-based case-control study <b>2020</b> , 17, e1003289		
235	Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker-based case-control study <b>2020</b> , 17, e1003289		
234	Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker-based case-control study <b>2020</b> , 17, e1003289		
233	Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay. <i>Alzheimer's and Dementia</i> , <b>2019</b> , 15, 1478-1488	1.2	22
232	Dementia, End of Life, and Euthanasia: A Survey Among Dementia Specialists Organized by the Belgian Dementia Council. <i>Journal of Alzheimer's Disease</i> , <b>2019</b> , 69, 989-1001	4.3	8
231	Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort. <i>Alzheimer's and Dementia</i> , <b>2019</b> , 15, 817-827	1.2	26

230	Semi-quantification and grading of amyloid PET: A project of the European Alzheimer's Disease Consortium (EADC). <i>NeuroImage: Clinical</i> , <b>2019</b> , 23, 101846	5.3	12
229	Inflammatory biomarkers in Alzheimer's disease plasma. <i>Alzheimer's and Dementia</i> , <b>2019</b> , 15, 776-787	1.2	74
228	Validation of the Erlangen Score Algorithm for Differential Dementia Diagnosis in Autopsy-Confirmed Subjects. <i>Journal of Alzheimer's Disease</i> , <b>2019</b> , 68, 1151-1159	4.3	6
227	Brief cognitive screening instruments for early detection of Alzheimer's disease: a systematic review. <i>Alzheimer's Research and Therapy</i> , <b>2019</b> , 11, 21	9	61
226	Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum. <i>Alzheimer's and Dementia</i> , <b>2019</b> , 15, 644-654	1.2	57
225	Loss of DPP6 in neurodegenerative dementia: a genetic player in the dysfunction of neuronal excitability. <i>Acta Neuropathologica</i> , <b>2019</b> , 137, 901-918	14.3	21
224	Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and F-FDG-PET imaging. <i>NeuroImage: Clinical</i> , <b>2019</b> , 22, 101771	5.3	62
223	Relevance of the interplay between amyloid and tau for cognitive impairment in early Alzheimer's disease. <i>Neurobiology of Aging</i> , <b>2019</b> , 79, 131-141	5.6	12
222	F-FDG PET, the early phases and the delivery rate of F-AV45 PET as proxies of cerebral blood flow in Alzheimer's disease: Validation against O-HO PET. <i>Alzheimer's and Dementia</i> , <b>2019</b> , 15, 1172-1182	1.2	16
221	Souvenaid in the management of mild cognitive impairment: an expert consensus opinion. <i>Alzheimer's Research and Therapy</i> , <b>2019</b> , 11, 73	9	14
220	The Use of Biomarkers and Genetic Screening to Diagnose Frontotemporal Dementia: Evidence and Clinical Implications. <i>Frontiers in Neuroscience</i> , <b>2019</b> , 13, 757	5.1	14
219	Limited engagement in, yet clear preferences for advance care planning in young-onset dementia: An exploratory interview-study with family caregivers. <i>Palliative Medicine</i> , <b>2019</b> , 33, 1166-1175	5.5	10
218	Pre-analytical stability of novel cerebrospinal fluid biomarkers. <i>Clinica Chimica Acta</i> , <b>2019</b> , 497, 204-211	6.2	8
217	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A $\beta$ tau, immunity and lipid processing. <i>Nature Genetics</i> , <b>2019</b> , 51, 414-430	36.3	917
216	P4-525: ASSOCIATION OF CSF TAU WITH HYPERPLASTICITY IN ALZHEIMER'S DISEASE <b>2019</b> , 15, P1515-P1516		
215	ASSOCIATIONS BETWEEN CEREBROSPINAL FLUID NEURODEGENERATIVE MARKERS, NEUROFILAMENT-LIGHT AND TOTAL TAU AND CEREBROVASCULAR IMAGING MARKERS <b>2019</b> , 15, P1626-P1627		
214	IC-P-130: ICOBRAIN DM: A NEW METHOD FOR HIPPOCAMPUS AND BRAIN LOBE SEGMENTATION IN ALZHEIMER'S DISEASE <b>2019</b> , 15, P107-P108		
213	A metabolite-based machine learning approach to diagnose Alzheimer-type dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , <b>2019</b> , 5, 888-888	6	29



212	Neurogranin as Cerebrospinal Fluid Biomarker for Alzheimer Disease: An Assay Comparison Study. <i>Clinical Chemistry</i> , <b>2018</b> , 64, 927-937	5.5	27
211	CFAI-Plus: Adding cognitive frailty as a new domain to the comprehensive frailty assessment instrument. <i>International Journal of Geriatric Psychiatry</i> , <b>2018</b> , 33, 941-947	3.9	16
210	Clinical variability and onset age modifiers in an extended Belgian GRN founder family. <i>Neurobiology of Aging</i> , <b>2018</b> , 67, 84-94	5.6	13
209	White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation. <i>Alzheimer's Research and Therapy</i> , <b>2018</b> , 10, 30	9	29
208	Diagnostic value of cerebrospinal fluid tau, neurofilament, and progranulin in definite frontotemporal lobar degeneration. <i>Alzheimer's Research and Therapy</i> , <b>2018</b> , 10, 31	9	29
207	Extended FTL D pedigree segregating a Belgian GRN-null mutation: neuropathological heterogeneity in one family. <i>Alzheimer's Research and Therapy</i> , <b>2018</b> , 10, 7	9	6
206	Cerebrospinal Fluid Biomarkers for Early and Differential Alzheimer's Disease Diagnosis. <i>Journal of Alzheimer's Disease</i> , <b>2018</b> , 62, 1199-1209	4.3	38
205	An intronic VNTR affects splicing of ABCA7 and increases risk of Alzheimer's disease. <i>Acta Neuropathologica</i> , <b>2018</b> , 135, 827-837	14.3	40
204	Prevalence of the apolipoprotein E $\epsilon$ 4 allele in amyloid $\beta$ positive subjects across the spectrum of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , <b>2018</b> , 14, 913-924	1.2	36
203	Rare nonsynonymous variants in SORT1 are associated with increased risk for frontotemporal dementia. <i>Neurobiology of Aging</i> , <b>2018</b> , 66, 181.e3-181.e10	5.6	12
202	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. <i>World Journal of Biological Psychiatry</i> , <b>2018</b> , 19, 244-328	3.8	148
201	A Retrospective Belgian Multi-Center MRI Biomarker Study in Alzheimer's Disease (REMEMBER). <i>Journal of Alzheimer's Disease</i> , <b>2018</b> , 63, 1509-1522	4.3	13
200	The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics. <i>Alzheimer's Research and Therapy</i> , <b>2018</b> , 10, 64	9	31
199	Detecting frail, older adults and identifying their strengths: results of a mixed-methods study. <i>BMC Public Health</i> , <b>2018</b> , 18, 191	4.1	24
198	Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer's disease: randomized, double-blind, placebo-controlled study. <i>Alzheimer's Research and Therapy</i> , <b>2018</b> , 10, 85	9	43
197	No supportive evidence for TIA1 gene mutations in a European cohort of ALS-FTD spectrum patients. <i>Neurobiology of Aging</i> , <b>2018</b> , 69, 293.e9-293.e11	5.6	11
196	Association of Cerebral Amyloid- $\beta$ Aggregation With Cognitive Functioning in Persons Without Dementia. <i>JAMA Psychiatry</i> , <b>2018</b> , 75, 84-95	14.5	94
195	Common and rare TBK1 variants in early-onset Alzheimer disease in a European cohort. <i>Neurobiology of Aging</i> , <b>2018</b> , 62, 245.e1-245.e7	5.6	12

194	P2-270: INCREASED CSF AMYLOID- $\beta$ -38 AND 1-40 CONCENTRATIONS IN INDIVIDUALS WITH MILD COGNITIVE IMPAIRMENT WITH TAU BUT WITHOUT AMYLOID PATHOPHYSIOLOGY <b>2018</b> , 14, P780-P781		
193	P3-233: PLASMA PRIMARY FATTY AMIDES ASSOCIATE TO CSF AMYLOID LEVELS AND ALZHEIMER'S DISEASE PROGRESSION IN THE EMIF-AD BIOMARKER DISCOVERY COHORT <b>2018</b> , 14, P1161-P1161		
192	P2-228: PRE-ANALYTICAL STABILITY OF NOVEL CEREBROSPINAL FLUID BIOMARKERS FOR DEMENTIA <b>2018</b> , 14, P755-P756		
191	O4-01-01: IN-DEPTH ANALYSIS OF AN ABCA7 VNTR IN ALZHEIMER'S DISEASE <b>2018</b> , 14, P1400-P1400		
190	F1-02-04: GENOMICS AND EPIGENOMICS ANALYSES IN THE EMIF-AD MULTIMODAL BIOMARKER DISCOVERY STUDY <b>2018</b> , 14, P204-P204		
189	P3-128: EXPLORING THE MOLECULAR MECHANISM OF NEURONAL HYPEREXCITABILITY IN DEMENTIA <b>2018</b> , 14, P1116-P1117		
188	P3-409: PERFORMANCE EVALUATION OF AUTOMATIC BRAIN MRI SUBSTRUCTURE SEGMENTATION WITH ICOBRAIN <b>2018</b> , 14, P1260-P1262		
187	Added Diagnostic Value of Cerebrospinal Fluid Biomarkers for Differential Dementia Diagnosis in an Autopsy-Confirmed Cohort. <i>Journal of Alzheimer's Disease</i> , <b>2018</b> , 63, 373-381	4.3	9
186	F1-02-02: DISCOVERY, REPLICATION AND EXTENSION STUDY OF PLASMA PROTEOMIC BIOMARKERS RELATING TO BRAIN AMYLOID BURDEN AND ALZHEIMER'S DISEASE PROGRESSION <b>2018</b> , 14, P201-P202		
185	F1-02-01: RELATING CSF MARKERS NEUROGRANIN, NEUROFILAMENT-LIGHT AND YKL-40 TO A $\beta$ APOE $\epsilon$ AND COGNITION: RESULTS FROM THE EMIF-AD MULTIMODAL BIOMARKER DISCOVERY STUDY <b>2018</b> , 14, P201-P201		
184	MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study. <i>Alzheimer's Research and Therapy</i> , <b>2018</b> , 10, 100	9	30
183	Randomized controlled trial to evaluate a prevention program for frail community-dwelling older adults: a D-SCOPE protocol. <i>BMC Geriatrics</i> , <b>2018</b> , 18, 194	4.1	6
182	P2-458: PREDICTING COGNITIVE DECLINE THROUGH STRUCTURAL MRI BIOMARKERS: RESULTS FROM THE EMIF-AD BIOMARKER DISCOVERY STUDY <b>2018</b> , 14, P895-P896		
181	F1-02-03: MRI PREDICTORS OF AMYLOID PATHOLOGY: RESULTS FROM THE EMIF-AD BIOMARKER DISCOVERY STUDY <b>2018</b> , 14, P202-P204		
180	Callosal circularity as an early marker for Alzheimer's disease. <i>NeuroImage: Clinical</i> , <b>2018</b> , 19, 516-526	5.3	5
179	Genetic screening in early-onset dementia patients with unclear phenotype: relevance for clinical diagnosis. <i>Neurobiology of Aging</i> , <b>2018</b> , 69, 292.e7-292.e14	5.6	14
178	Identifying frailty risk profiles of home-dwelling older people: focus on sociodemographic and socioeconomic characteristics. <i>Aging and Mental Health</i> , <b>2017</b> , 21, 1031-1039	3.5	30
177	Investigating the role of ALS genes CHCHD10 and TUBA4A in Belgian FTD-ALS spectrum patients. <i>Neurobiology of Aging</i> , <b>2017</b> , 51, 177.e9-177.e16	5.6	43



176	Selecting A $\beta$ isoforms for an Alzheimer's disease cerebrospinal fluid biomarker panel. <i>Biomarkers in Medicine</i> , <b>2017</b> , 11, 169-178	2.3	10
175	How to handle adsorption of cerebrospinal fluid amyloid $\beta$ (1-42) in laboratory practice? Identifying problematic handlings and resolving the issue by use of the A $\beta$ /A $\beta$ ratio. <i>Alzheimer's and Dementia</i> , <b>2017</b> , 13, 885-892	1.2	44
174	BACE1 Dynamics Upon Inhibition with a BACE Inhibitor and Correlation to Downstream Alzheimer's Disease Markers in Elderly Healthy Participants. <i>Journal of Alzheimer's Disease</i> , <b>2017</b> , 56, 1437-1449	4.3	23
173	The impact of automated hippocampal volumetry on diagnostic confidence in patients with suspected Alzheimer's disease: A European Alzheimer's Disease Consortium study. <i>Alzheimer's and Dementia</i> , <b>2017</b> , 13, 1013-1023	1.2	22
172	Clinical Evidence of Disease Anticipation in Families Segregating a C9orf72 Repeat Expansion. <i>JAMA Neurology</i> , <b>2017</b> , 74, 445-452	17.2	50
171	Deleterious ABCA7 mutations and transcript rescue mechanisms in early onset Alzheimer's disease. <i>Acta Neuropathologica</i> , <b>2017</b> , 134, 475-487	14.3	34
170	Consensus guidelines for lumbar puncture in patients with neurological diseases. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2017</b> , 8, 111-126	5.2	128
169	The frequency and influence of dementia risk factors in prodromal Alzheimer's disease. <i>Neurobiology of Aging</i> , <b>2017</b> , 56, 33-40	5.6	19
168	Validation of the Semiquantitative Static SUVR Method for F-AV45 PET by Pharmacokinetic Modeling with an Arterial Input Function. <i>Journal of Nuclear Medicine</i> , <b>2017</b> , 58, 1483-1489	8.9	23
167	Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. <i>Alzheimer's and Dementia</i> , <b>2017</b> , 13, 274-284	1.2	91
166	Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment. <i>Alzheimer's and Dementia</i> , <b>2017</b> , 13, 285-295	1.2	88
165	TBK1 Mutation Spectrum in an Extended European Patient Cohort with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. <i>Human Mutation</i> , <b>2017</b> , 38, 297-309	4.7	66
164	Severe bilateral subdural hematomas as a complication of diagnostic lumbar puncture for possible Alzheimer's disease. <i>Clinical Neurology and Neurosurgery</i> , <b>2017</b> , 152, 95-96	2	4
163	Alzheimer's disease and driving: review of the literature and consensus guideline from Belgian dementia experts and the Belgian road safety institute endorsed by the Belgian Medical Association. <i>Acta Neurologica Belgica</i> , <b>2017</b> , 117, 811-819	1.5	9
162	Neurogranin and tau in cerebrospinal fluid and plasma of patients with acute ischemic stroke. <i>BMC Neurology</i> , <b>2017</b> , 17, 170	3.1	44
161	No added diagnostic value of non-phosphorylated tau fraction (p-tau) in CSF as a biomarker for differential dementia diagnosis. <i>Alzheimer's Research and Therapy</i> , <b>2017</b> , 9, 49	9	11
160	Differential role of CSF fatty acid binding protein 3, Synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia. <i>Alzheimer's Research and Therapy</i> , <b>2017</b> , 9, 52	9	69
159	Alzheimer's disease CSF biomarkers: clinical indications and rational use. <i>Acta Neurologica Belgica</i> , <b>2017</b> , 117, 591-602	1.5	57

158	[P4075]: THE MAPT P.ARG406TRP IS A FOUNDER MUTATION IN BELGIUM AND PRESENTS WITH AN ALZHEIMER DISEASE DEMENTIA-LIKE PHENOTYPE <b>2017</b> , 13, P1286-P1286			1
157	[P4069]: A PROSPECTIVE NEUROGENETIC STUDY ON EARLY-ONSET DEMENTIA IN PATIENTS WITH UNCLEAR INITIAL DIAGNOSIS OF DEGENERATIVE DEMENTIA <b>2017</b> , 13, P1284-P1284			
156	[P1037]: DIFFERENTIAL ROLE OF CSF FATTY ACID BINDING PROTEIN 3, SYNNUCLEIN AND ALZHEIMER'S DISEASE CORE BIOMARKERS IN LEWY BODY DISORDERS AND ALZHEIMER'S DEMENTIA <b>2017</b> , 13, P334-P335			
155	[P2063]: EARLY FRAME 18F-AV45 AND 18F-FDG-PET AS PROXIES OF CBF: COMPARISON TO 15O-H2O PET DATA <b>2017</b> , 13, P763-P764			2
154	[P4039]: FDG-PET POWER TO PREDICT MEMORY DECLINE IN ALZHEIMER'S DISEASE DEPENDS ON DISEASE PHASE AND AMYLOID AND TAU STATUS <b>2017</b> , 13, P1366-P1367			
153	[P1089]: DISCOVERY, REPLICATION AND EXTENSION STUDY OF PLASMA PROTEOMIC BIOMARKERS RELATING TO BRAIN AMYLOID BURDEN (CSF A $\beta$ OR AMYLOID-PET) IN THE EMIF-AD BIOMARKER DISCOVERY COHORT <b>2017</b> , 13, P361-P362			
152	[P1087]: CHARACTERIZATION OF SUSPECTED NON-ALZHEIMER'S DISEASE PATHOPHYSIOLOGY (SNAP) IN INDIVIDUALS WITH MILD COGNITIVE IMPAIRMENT USING NEUROIMAGING <b>2017</b> , 13, P414-P414			
151	[P2016]: TRANSCRIPTOME ANALYSIS IN BLOOD AND BRAIN IDENTIFIES GENE EXPRESSION REGULATION AND CORRESPONDING QUANTITATIVE TRAIT LOCI IN ALZHEIMER'S DISEASE <b>2017</b> , 13, P651-P651			
150	[P2011]: AMYLOID- $\beta$ 2 (A $\beta$ 2) DIFFERENTIALLY CORRELATES WITH CSF TOTAL AND HYPERPHOSPHORYLATED TAU IN AN AMYLOID-POSITIVE VERSUS AMYLOID-NEGATIVE EARLY PRODROMAL AND ASYMPTOMATIC AT-RISK FOR AD POPULATION <b>2017</b> , 13, P690-P691			
149	[O2005]: DELETERIOUS ABCA7 MUTATIONS CONTRIBUTE TO EARLY-ONSET ALZHEIMER'S DISEASE AND ARE SUBJECT TO TRANSCRIPT RESCUE MECHANISMS <b>2017</b> , 13, P589-P590			
148	The Cerebrospinal Fluid A $\beta$ -42/A $\beta$ -40 Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer's Disease in a Clinical Setting. <i>Journal of Alzheimer's Disease</i> , <b>2017</b> , 60, 561-576	4.3		54
147	Multicenter Analytical Validation of A $\beta$ 0 Immunoassays. <i>Frontiers in Neurology</i> , <b>2017</b> , 8, 310	4.1		9
146	A simulation study on the impact of the blood flow-dependent component in [18F]AV45 SUVR in Alzheimer's disease. <i>PLoS ONE</i> , <b>2017</b> , 12, e0189155	3.7		8
145	Non-Phosphorylated Tau as a Potential Biomarker of Alzheimer's Disease: Analytical and Diagnostic Characterization. <i>Journal of Alzheimer's Disease</i> , <b>2017</b> , 55, 159-170	4.3		19
144	EEG Dominant Frequency Peak Differentiates Between Alzheimer's Disease and Frontotemporal Lobar Degeneration. <i>Journal of Alzheimer's Disease</i> , <b>2017</b> , 55, 53-58	4.3		10
143	Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team. <i>Journal of Alzheimer's Disease</i> , <b>2017</b> , 55, 19-35	4.3		29
142	Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study. <i>Alzheimer's and Dementia</i> , <b>2016</b> , 12, 154-163	1.2		129
141	Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics. <i>Journal of Alzheimer's Disease</i> , <b>2016</b> , 52, 51-64	4.3		17

140	Mutations in glucocerebrosidase are a major genetic risk factor for Parkinson's disease and increase susceptibility to dementia in a Flanders-Belgian cohort. <i>Neuroscience Letters</i> , <b>2016</b> , 629, 160-164	3.3	19
139	P4-159: Screening and Recruitment Experience When Using Biomarker-Based Population Definition in Alzheimer's Disease Studies <b>2016</b> , 12, P1075-P1076		
138	P3-209: Impact of Biomarkers On Diagnostic Confidence in Clinical Assessment of Patients with Suspected Alzheimer's Disease and High Diagnostic Uncertainty: An EADC Study <b>2016</b> , 12, P904-P905		
137	Impact of frequent cerebrospinal fluid sampling on A $\beta$ levels: systematic approach to elucidate influencing factors. <i>Alzheimer's Research and Therapy</i> , <b>2016</b> , 8, 21	9	10
136	Validation of soluble amyloid- $\beta$ precursor protein assays as diagnostic CSF biomarkers for neurodegenerative diseases. <i>Journal of Neurochemistry</i> , <b>2016</b> , 137, 112-21	6	15
135	Clinical features of TBK1 carriers compared with C9orf72, GRN and non-mutation carriers in a Belgian cohort. <i>Brain</i> , <b>2016</b> , 139, 452-67	11.2	67
134	Next Generation Brain Health Depends on Early Alzheimer Disease Diagnosis: From a Timely Diagnosis to Future Population Screening. <i>Journal of the American Medical Directors Association</i> , <b>2016</b> , 17, 452-3	5.9	13
133	The Cerebrospinal Fluid Neurogranin/BACE1 Ratio is a Potential Correlate of Cognitive Decline in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , <b>2016</b> , 53, 1523-38	4.3	40
132	Diagnostic Impact of Cerebrospinal Fluid Biomarker (Pre-)Analytical Variability in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , <b>2016</b> , 51, 97-106	4.3	17
131	A Decade of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Belgium. <i>Journal of Alzheimer's Disease</i> , <b>2016</b> , 54, 383-95	4.3	31
130	sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers. <i>EMBO Molecular Medicine</i> , <b>2016</b> , 8, 466-76		256
129	Validation of microRNAs in Cerebrospinal Fluid as Biomarkers for Different Forms of Dementia in a Multicenter Study. <i>Journal of Alzheimer's Disease</i> , <b>2016</b> , 52, 1321-33	4.3	34
128	P2-299: Brief Neuropsychological Screening Tests for the Detection of Alzheimer's Disease in an Early Phase: A Systematic Review <b>2016</b> , 12, P748-P748		
127	P4-122: Prevalence of Vascular Risk Factors in Different Stages of Prodromal Alzheimer's Disease and Its Influence on Cognitive Decline <b>2016</b> , 12, P1059-P1061		
126	P4-194: Blood Flow Independent Quantification of [18F]-AV45 PET Using Model-Based Kinetics With a Metabolite-Corrected Arterial Input Function <b>2016</b> , 12, P1097-P1098		
125	P1-176: CSF Exploratory Biomarker Study for (DIFFERENTIAL) Diagnosis of Frontotemporal Lobar Degeneration <b>2016</b> , 12, P471-P471		
124	P1-320: Volumetric Brain MRI of Different Regions, Including The Hippocampus, in The Alzheimer's Disease Spectrum: A Systematic Review <b>2016</b> , 12, P547-P548		
123	P1-407: Cognitive Frailty: A New Domain Added to The Comprehensive Frailty Assessment <b>2016</b> , 12, P590-P590		1

122	P2-153: Diagnostic Performance of Non-Phosphorylated TAU Fraction (PTAU REL) in CSF as Biomarker for Differential Dementia Diagnosis <b>2016</b> , 12, P672-P673		
121	P3-258: Resting State Functional Mri in Alzheimer's Disease: an Innovative Approach for Robust Extraction of the Default Mode Network <b>2016</b> , 12, P930-P930		
120	P4-120: Increased CSF Levels of Biomarkers for Neurodegeneration in FTLD-GRN Mutation Carriers <b>2016</b> , 12, P1058-P1059		
119	O1-11-02: Combination of Cerebrospinal Fluid H-FABP and Core Alzheimer's Disease Biomarkers Improves the Differential Diagnosis of Neurodegenerative Disorders <b>2016</b> , 12, P201-P202		1
118	O4-09-03: Eeg Dominant Frequency Peak Differentiates Between Alzheimer's Disease and Frontotemporal Lobar Degeneration <b>2016</b> , 12, P354-P355		
117	P1-170: A Decade of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Belgium <b>2016</b> , 12, P467-P468		
116	P4-314: Discordance Between Amyloid-PET and CSF Amyloid- $\beta$ for Diagnosing Alzheimer's Disease in a Clinical Setting <b>2016</b> , 12, P1154-P1154		
115	P4-322: CSF Biomarkers to Predict Rate of Cognitive Decline in Alzheimer's Disease <b>2016</b> , 12, P1157-P1157		
114	P4-324: Plasma Neurofilament Light Concentration Predicts Long-Term Outcome an Acute Stroke <b>2016</b> , 12, P1158-P1158		
113	Phenotypic characteristics of Alzheimer patients carrying an ABCA7 mutation. <i>Neurology</i> , <b>2016</b> , 86, 2126-2133		19
112	Profiling the dynamics of CSF and plasma A $\beta$ reduction after treatment with JNJ-54861911, a potent oral BACE inhibitor. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , <b>2016</b> , 2, 202-212	6	42
111	SolCos model-based individual reminiscence for older adults with mild to moderate dementia in nursing homes: a randomized controlled intervention study. <i>Journal of Psychiatric and Mental Health Nursing</i> , <b>2016</b> , 23, 568-575	2.4	21
110	Mutated CTSF in adult-onset neuronal ceroid lipofuscinosis and FTD. <i>Neurology: Genetics</i> , <b>2016</b> , 2, e102	3.8	13
109	Diagnostic value of MIBG cardiac scintigraphy for differential dementia diagnosis. <i>International Journal of Geriatric Psychiatry</i> , <b>2015</b> , 30, 864-9	3.9	24
108	Association of cerebrospinal fluid prion protein levels and the distinction between Alzheimer disease and Creutzfeldt-Jakob disease. <i>JAMA Neurology</i> , <b>2015</b> , 72, 267-75	17.2	55
107	Clinical utility and applicability of biomarker-based diagnostic criteria for Alzheimer's disease: a BeDeCo survey. <i>Acta Neurologica Belgica</i> , <b>2015</b> , 115, 547-55	1.5	7
106	Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. <i>Brain</i> , <b>2015</b> , 138, 1327-38	11.2	211
105	The monoaminergic footprint of depression and psychosis in dementia with Lewy bodies compared to Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , <b>2015</b> , 7, 7	9	30

104	Tau monoclonal antibody generation based on humanized yeast models: impact on Tau oligomerization and diagnostics. <i>Journal of Biological Chemistry</i> , <b>2015</b> , 290, 4059-74	5.4	16
103	Psychosis associated behavioral and psychological signs and symptoms in mild cognitive impairment and Alzheimer's dementia. <i>Aging and Mental Health</i> , <b>2015</b> , 19, 818-28	3.5	16
102	Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects. <i>Brain</i> , <b>2015</b> , 138, 2701-15.2	15.2	86
101	Mutations in ABCA7 in a Belgian cohort of Alzheimer's disease patients: a targeted resequencing study. <i>Lancet Neurology</i> , <b>2015</b> , 14, 814-822	24.1	95
100	Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study. <i>Neurobiology of Aging</i> , <b>2015</b> , 36, 2587-96	5.6	29
99	A 22-single nucleotide polymorphism Alzheimer's disease risk score correlates with family history, onset age, and cerebrospinal fluid Aβ2. <i>Alzheimer's and Dementia</i> , <b>2015</b> , 11, 1452-1460	1.2	69
98	Agitation-associated behavioral symptoms in mild cognitive impairment and Alzheimer's dementia. <i>Aging and Mental Health</i> , <b>2015</b> , 19, 247-57	3.5	19
97	Genetic variability in SQSTM1 and risk of early-onset Alzheimer dementia: a European early-onset dementia consortium study. <i>Neurobiology of Aging</i> , <b>2015</b> , 36, 2005.e15-22	5.6	29
96	Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , <b>2015</b> , 313, 1924-38	27.4	842
95	Importance and impact of preanalytical variables on Alzheimer disease biomarker concentrations in cerebrospinal fluid. <i>Clinical Chemistry</i> , <b>2015</b> , 61, 734-43	5.5	47
94	Reduced secreted clusterin as a mechanism for Alzheimer-associated CLU mutations. <i>Molecular Neurodegeneration</i> , <b>2015</b> , 10, 30	19	34
93	C-terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , <b>2015</b> , 11, 1461-1469	1.2	95
92	Loss of TBK1 is a frequent cause of frontotemporal dementia in a Belgian cohort. <i>Neurology</i> , <b>2015</b> , 85, 2116-25	6.5	119
91	Apraxic agraphia following thalamic damage: Three new cases. <i>Brain and Language</i> , <b>2015</b> , 150, 153-65	2.9	2
90	O3-13-06: Targeted re-sequencing of sorl1 in early-onset Alzheimer's dementia: The european early onset dementia consortium <b>2015</b> , 11, P253-P253		
89	O4-11-03: Limited impact of CSF biomarkers variability on clinical diagnosis in autopsy-confirmed Alzheimer's disease <b>2015</b> , 11, P296-P297		
88	P4-232: A monoclonal antibody-based elisa for neurogranin <b>2015</b> , 11, P869-P869		1
87	P4-248: Resting state functional MRI as a possible biomarker for Alzheimer's disease: An innovative approach for robust extraction of the default mode network <b>2015</b> , 11, P876-P876		

86	Diffusion Kurtosis Imaging: A Possible MRI Biomarker for AD Diagnosis?. <i>Journal of Alzheimer's Disease</i> , <b>2015</b> , 48, 937-48	4.3	35
85	O4-11-04: Performance and complications of lumbar puncture in memory clinics: Results of the multicenter Ip feasibility study <b>2015</b> , 11, P297-P297		1
84	Investigating the role of filamin C in Belgian patients with frontotemporal dementia linked to GRN deficiency in FTLT-DTP brains. <i>Acta Neuropathologica Communications</i> , <b>2015</b> , 3, 68	7.3	12
83	Cerebrospinal Fluid P-Tau181P: Biomarker for Improved Differential Dementia Diagnosis. <i>Frontiers in Neurology</i> , <b>2015</b> , 6, 138	4.1	38
82	A Practical Guide to Immunoassay Method Validation. <i>Frontiers in Neurology</i> , <b>2015</b> , 6, 179	4.1	223
81	P4-249: Admetrix: A new method for atrophy quantification in Alzheimer's disease <b>2015</b> , 11, P876-P876		1
80	P1-115: Consensus guidelines to perform lumbar puncture for CSF sampling in patients with neurological conditions <b>2015</b> , 11, P384-P384		1
79	P3-017: Rare variants in PLD3 do not increase risk in a belgian cohort of early-onset Alzheimer dementia patients <b>2015</b> , 11, P626-P626		
78	P4-194: The identification of high-penetrant loss-of-function mutations in abca7 in Alzheimer's disease <b>2015</b> , 11, P854-P854		
77	Diagnostic Accuracy of Cerebrospinal Fluid Amyloid- $\beta$ isoforms for Early and Differential Dementia Diagnosis. <i>Journal of Alzheimer's Disease</i> , <b>2015</b> , 45, 813-22	4.3	75
76	Overdiagnosing Vascular Dementia using Structural Brain Imaging for Dementia Work-Up. <i>Journal of Alzheimer's Disease</i> , <b>2015</b> , 45, 1039-43	4.3	15
75	Techniques, Contraindications, and Complications of CSF Collection Procedures <b>2015</b> , 35-57		7
74	Risk factors for poststroke depression: identification of inconsistencies based on a systematic review. <i>Journal of Geriatric Psychiatry and Neurology</i> , <b>2014</b> , 27, 147-58	3.8	88
73	Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. <i>Lancet Neurology</i> , <b>2014</b> , 13, 614-29	24.1	1985
72	Biobanking of CSF: international standardization to optimize biomarker development. <i>Clinical Biochemistry</i> , <b>2014</b> , 47, 288-92	3.5	68
71	Rationale and clinical data supporting nutritional intervention in Alzheimer's disease. <i>Acta Clinica Belgica</i> , <b>2014</b> , 69, 17-24	1.8	33
70	The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. <i>Alzheimer's and Dementia</i> , <b>2014</b> , 10, 808-17	1.2	132
69	Rare mutations in SQSTM1 modify susceptibility to frontotemporal lobar degeneration. <i>Acta Neuropathologica</i> , <b>2014</b> , 128, 397-410	14.3	83



68	Increased CSF $\beta$ -synuclein levels in Alzheimer's disease: correlation with tau levels. <i>Alzheimer's and Dementia</i> , <b>2014</b> , 10, S290-8	1.2	54
67	Monoaminergic neurotransmitter alterations in postmortem brain regions of depressed and aggressive patients with Alzheimer's disease. <i>Neurobiology of Aging</i> , <b>2014</b> , 35, 2691-2700	5.6	52
66	Validation of the AD-CSF-index in autopsy-confirmed Alzheimer's disease patients and healthy controls. <i>Journal of Alzheimer's Disease</i> , <b>2014</b> , 41, 903-9	4.3	22
65	Brain region-specific monoaminergic correlates of neuropsychiatric symptoms in Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , <b>2014</b> , 41, 819-33	4.3	43
64	P1-053: OLFACTORY RECEPTOR COPY NUMBER VARIATION INVOLVED IN ALZHEIMER'S DISEASE <b>2014</b> , 10, P322-P323		
63	Depression in mild cognitive impairment is associated with progression to Alzheimer's disease: a longitudinal study. <i>Journal of Alzheimer's Disease</i> , <b>2014</b> , 42, 1239-50	4.3	82
62	Poststroke depression and its multifactorial nature: results from a prospective longitudinal study. <i>Journal of the Neurological Sciences</i> , <b>2014</b> , 347, 159-66	3.2	48
61	TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. <i>Science Translational Medicine</i> , <b>2014</b> , 6, 243ra86	17.5	436
60	O1-04-04: ANALYSIS OF SQSTM1 IN PATIENTS WITH EARLY-ONSET ALZHEIMER'S DISEASE <b>2014</b> , 10, P135-P136		
59	Behavioral symptoms in mild cognitive impairment as compared with Alzheimer's disease and healthy older adults. <i>International Journal of Geriatric Psychiatry</i> , <b>2013</b> , 28, 265-75	3.9	38
58	Clinical indications for analysis of Alzheimer's disease CSF biomarkers. <i>Revue Neurologique</i> , <b>2013</b> , 169, 709-14	3	16
57	A pan-European study of the C9orf72 repeat associated with FTLTLD: geographic prevalence, genomic instability, and intermediate repeats. <i>Human Mutation</i> , <b>2013</b> , 34, 363-73	4.7	208
56	CSF biomarker variability in the Alzheimer's Association quality control program. <i>Alzheimer's and Dementia</i> , <b>2013</b> , 9, 251-61	1.2	289
55	Distinct clinical characteristics of C9orf72 expansion carriers compared with GRN, MAPT, and nonmutation carriers in a Flanders-Belgian FTLTLD cohort. <i>JAMA Neurology</i> , <b>2013</b> , 70, 365-73	17.2	77
54	A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. <i>JAMA Neurology</i> , <b>2013</b> , 70, 727-35	17.2	285
53	Longitudinal stability of cerebrospinal fluid biomarker levels: fulfilled requirement for pharmacodynamic markers in Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , <b>2013</b> , 33, 807-22	4.3	28
52	Cerebrospinal fluid A $\beta$ -40 improves differential dementia diagnosis in patients with intermediate P-tau181P levels. <i>Journal of Alzheimer's Disease</i> , <b>2013</b> , 36, 759-67	4.3	65
51	Amyloid pathology influences a $\beta$ -42 cerebrospinal fluid levels in dementia with lewy bodies. <i>Journal of Alzheimer's Disease</i> , <b>2013</b> , 35, 137-46	4.3	42

50	Comparison of two analytical platforms for the clinical qualification of Alzheimer's disease biomarkers in pathologically-confirmed dementia. <i>Journal of Alzheimer's Disease</i> , <b>2013</b> , 33, 117-31	4.3	34
49	A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: a gene identification study. <i>Lancet Neurology</i> , <b>2012</b> , 11, 54-65	24.1	489
48	The genetics and neuropathology of frontotemporal lobar degeneration. <i>Acta Neuropathologica</i> , <b>2012</b> , 124, 353-72	14.3	206
47	Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. <i>Alzheimer's and Dementia</i> , <b>2012</b> , 8, 65-73	1.2	210
46	Ataxin-2 polyQ expansions in FTLD-ALS spectrum disorders in Flanders-Belgian cohorts. <i>Neurobiology of Aging</i> , <b>2012</b> , 33, 1004.e17-20	5.6	27
45	Both common variations and rare non-synonymous substitutions and small insertion/deletions in CLU are associated with increased Alzheimer risk. <i>Molecular Neurodegeneration</i> , <b>2012</b> , 7, 3	19	66
44	Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. <i>Biomarkers in Medicine</i> , <b>2012</b> , 6, 419-30	2.3	230
43	The role of CSF biomarkers in the diagnostic work-up of mixed vascular-degenerative dementia. <i>Journal of the Neurological Sciences</i> , <b>2012</b> , 322, 197-9	3.2	7
42	The impact of cerebrospinal fluid biomarkers on the diagnosis of Alzheimer's disease. <i>Molecular Diagnosis and Therapy</i> , <b>2012</b> , 16, 135-41	4.5	20
41	No association of PGRN 3'UTR rs5848 in frontotemporal lobar degeneration. <i>Neurobiology of Aging</i> , <b>2011</b> , 32, 754-5	5.6	38
40	Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. <i>Nature Genetics</i> , <b>2011</b> , 43, 429-35	36.3	1421
39	TMEM106B is associated with frontotemporal lobar degeneration in a clinically diagnosed patient cohort. <i>Brain</i> , <b>2011</b> , 134, 808-15	11.2	90
38	Follow-up study of susceptibility loci for Alzheimer's disease and onset age identified by genome-wide association. <i>Journal of Alzheimer's Disease</i> , <b>2010</b> , 19, 1169-75	4.3	27
37	Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. <i>Archives of Neurology</i> , <b>2010</b> , 67, 949-56		344
36	Added diagnostic value of CSF biomarkers in differential dementia diagnosis. <i>Neurobiology of Aging</i> , <b>2010</b> , 31, 1867-76	5.6	53
35	O1-03-01: In-depth molecular genetic analysis of CLU in Alzheimer's disease <b>2010</b> , 6, S73-S74		
34	Relation between frontal lobe symptoms and dementia severity within and across diagnostic dementia categories. <i>International Journal of Geriatric Psychiatry</i> , <b>2010</b> , 25, 1186-95	3.9	10
33	Clinical heterogeneity in 3 unrelated families linked to VCP p.Arg159His. <i>Neurology</i> , <b>2009</b> , 73, 626-32	6.5	73

32	Serum biomarker for progranulin-associated frontotemporal lobar degeneration. <i>Annals of Neurology</i> , <b>2009</b> , 65, 603-9	9.4	185
31	Relative contribution of simple mutations vs. copy number variations in five Parkinson disease genes in the Belgian population. <i>Human Mutation</i> , <b>2009</b> , 30, 1054-61	4.7	52
30	Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. <i>Nature Genetics</i> , <b>2009</b> , 41, 1094-9	36.3	1819
29	Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. <i>Nature Genetics</i> , <b>2009</b> , 41, 1088-93	36.3	2018
28	Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau(181P). <i>Neurochemistry International</i> , <b>2009</b> , 55, 214-8	4.4	117
27	No correlation between time-linked plasma and CSF Abeta levels. <i>Neurochemistry International</i> , <b>2009</b> , 55, 820-5	4.4	46
26	The dopaminergic neurotransmitter system is associated with aggression and agitation in frontotemporal dementia. <i>Neurochemistry International</i> , <b>2008</b> , 52, 1052-60	4.4	63
25	Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia. <i>Neurobiology of Aging</i> , <b>2008</b> , 29, 1143-59	5.6	181
24	No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer's disease. <i>Brain</i> , <b>2007</b> , 130, 2320-6	11.2	95
23	Alzheimer and Parkinson diagnoses in progranulin null mutation carriers in an extended founder family. <i>Archives of Neurology</i> , <b>2007</b> , 64, 1436-46		124
22	A Belgian ancestral haplotype harbours a highly prevalent mutation for 17q21-linked tau-negative FTLD. <i>Brain</i> , <b>2006</b> , 129, 841-52	11.2	82
21	Neuropsychological and behavioural correlates of CSF biomarkers in dementia. <i>Neurochemistry International</i> , <b>2006</b> , 48, 286-95	4.4	50
20	Dose dependent effect of APOE epsilon4 on behavioral symptoms in frontal lobe dementia. <i>Neurobiology of Aging</i> , <b>2006</b> , 27, 285-92	5.6	60
19	Behavioural and neuropsychological correlates of frontal lobe features in dementia. <i>Psychological Medicine</i> , <b>2006</b> , 36, 1173-82	6.9	24
18	Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. <i>Nature</i> , <b>2006</b> , 442, 920-4	50.4	1212
17	The Middelheim Frontality Score: a behavioural assessment scale that discriminates frontotemporal dementia from Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , <b>2005</b> , 20, 70-9	3.9	59
16	Neuropsychiatric symptoms of dementia: cross-sectional analysis from a prospective, longitudinal Belgian study. <i>International Journal of Geriatric Psychiatry</i> , <b>2005</b> , 20, 1028-37	3.9	91
15	High-density SNP haplotyping suggests altered regulation of tau gene expression in progressive supranuclear palsy. <i>Human Molecular Genetics</i> , <b>2005</b> , 14, 3281-92	5.6	144

14	Correlations between cognitive, behavioural and psychological findings and levels of vitamin B12 and folate in patients with dementia. <i>International Journal of Geriatric Psychiatry</i> , <b>2004</b> , 19, 365-70	3.9	40
13	5-HT2A receptor polymorphism may modulate antipsychotic treatment response in Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , <b>2004</b> , 19, 1108-9	3.9	2
12	Amino acids and biogenic amines in cerebrospinal fluid of patients with Parkinson's disease. <i>Neurochemical Research</i> , <b>2003</b> , 28, 1145-50	4.6	53
11	Prospective Belgian study of neurodegenerative and vascular dementia: APOE genotype effects. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2003</b> , 74, 1148-51	5.5	85
10	Recurrent transient ischemic attacks in a 15-year-old boy with beta-thalassemia minor and thrombophilia. Contribution of perfusion SPECT to clinical diagnosis. <i>Acta Neurologica Belgica</i> , <b>2003</b> , 103, 99-102	1.5	2
9	Headache as only symptom in multiple cervical artery dissection. <i>Headache</i> , <b>2001</b> , 41, 509-11	4.2	9
8	Biological and genetic markers of sporadic Alzheimer's disease. <i>Acta Medica Okayama</i> , <b>2001</b> , 55, 55-63	0.5	
7	Loss of psychic self-activation after paramedian bithalamic infarction. <i>Stroke</i> , <b>2000</b> , 31, 1762-5	6.7	64
6	Experimental autoimmune encephalomyelitis: An animal model for multiple sclerosis. <i>Neuroscience Research Communications</i> , <b>2000</b> , 26, 193-206		8
5	Unchanged levels of interleukins, neopterin, interferon-gamma and tumor necrosis factor-alpha in cerebrospinal fluid of patients with dementia of the Alzheimer type. <i>Neurochemistry International</i> , <b>1999</b> , 34, 523-30	4.4	61
4	Behavioral effects of vigabatrin correlated with whole brain gamma-aminobutyric acid metabolism in audiogenic sensitive rats. <i>Arzneimittelforschung</i> , <b>1998</b> , 48, 713-6		4
3	Functional anatomy, vascularisation and pathology of the human thalamus. <i>Acta Neurologica Belgica</i> , <b>1998</b> , 98, 252-65	1.5	24
2	Genome-wide association study of Alzheimer's disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset		1
1	New insights on the genetic etiology of Alzheimer's and related dementia		25